M25-709 GOG 3126 (FLORENZA): A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and E

Skip to Content

JavaScript has been disabled within your browser, the content or the functionality of this web page can be limited or unavailable.

There is no panel matching the key "Alert---Site-Wide-Ribbon"

Popular Searches

Looking for Something Else?

There is no panel matching the key "Alert---Site-Wide"

Back to Results

M25-709 GOG 3126 (FLORENZA): A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Mirvetuximab Soravtansine in Subjects With Ovarian Cancer

Objective

Clinical Trial Details

Principal Investigator(s)

David Starks, MD

Clinical Trial Categories

Cancer
Gynecologic Cancer

Contact

Gynecology Breast Coordinators at 605-322-7536
or gyn.breastresearch@avera.org

Location

Avera Cancer Institute — Sioux Falls
1000 E 23rd St
Suite 340
Sioux Falls, SD 57105
Main: 605-322-3000